Episode 66: FDA Accelerated Approvals and COI Phenomenons With Bishal Gyawali

Episode 66: FDA Accelerated Approvals and COI Phenomenons With Bishal Gyawali

Chadi welcomes back Bishal Gyawali, MD, PhD, Queen’s University Cancer Research Institute (Canada), to the show to discuss the history of the FDA’s accelerated approval regulatory pathway, how it is sometimes abused, how low-level surrogate endpoints are being used for approval, what happens (and what should happen) when confirmatory trials do not confirm clinical benefit for drugs approved through this pathway, how conflicts of interest may impact some regulatory decisions, and so much more. Dr. Gyawali raises some thought-provoking questions and critical points in this deep, nuanced discussion.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 206: Fireside Chat With Joe Mikhael, the CMO of the IMF

Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding

Read More

Episode 205: Multi-Cancer Early Detection (MCED): Now and Later

Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary

Read More